![](/images/graphics-bg.png)
Survival Outcomes and Tumor IMP3 Expression in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma
Joint Authors
Tantravahi, Srinivas K.
Albertson, Daniel
Ravulapati, Sowmya
Poole, Austin
Patel, Shiven B.
Hawatmeh, Jamil S.
Straubhar, Alli M.
Liu, Ting
Stenehjem, David D.
Agarwal, Archana M.
Agarwal, Neeraj
Source
Issue
Vol. 2015, Issue 2015 (31 Dec. 2015), pp.1-6, 6 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2015-01-20
Country of Publication
Egypt
No. of Pages
6
Main Subjects
Abstract EN
Metastatic renal cell carcinoma with sarcomatoid histology (SmRCC) is associated with poor survival.
No data is available from randomized trials on the efficacy of vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) inhibitors in SmRCC.
We identified SmRCC patients from a single institutional database.
To identify predictive and prognostic biomarkers, immunohistochemistry (IHC) analysis was performed on the tumor samples for downstream targets of VEGF and mTOR pathways.
Survival outcomes were stratified by IHC analysis, extent of sarcomatoid component, Memorial Sloan-Kettering Cancer Center (MSKCC), and Heng risk criteria.
Twenty-seven patients with SmRCC were included.
First line therapy included targeted therapy ( n = 19 ), immunotherapy ( n = 4 ), cytotoxic chemotherapy ( n = 1 ), and no treatment ( n = 3 ).
Median OS was 8.2 months (95% CI 3.8–14.2 months).
Median survival in months, based on MSKCC and Heng risk groups, was favorable 89.3 versus 84.5, intermediate 9.5 versus 12.7, and poor 3.9 versus 5.1.
None of the IHC markers predicted outcomes of treatment with VEGF or mTOR inhibitors.
Only tumor IMP3 expression was associated with inferior OS, although not statistically significant (IMP3 negative 14.2 versus IMP3 positive 4.9 months; HR 0.46, 95% CI 0.16–1.21; P = 0.12 ).
The study was limited by small sample size.
American Psychological Association (APA)
Tantravahi, Srinivas K.& Albertson, Daniel& Agarwal, Archana M.& Ravulapati, Sowmya& Poole, Austin& Patel, Shiven B.…[et al.]. 2015. Survival Outcomes and Tumor IMP3 Expression in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma. Journal of Oncology،Vol. 2015, no. 2015, pp.1-6.
https://search.emarefa.net/detail/BIM-1069560
Modern Language Association (MLA)
Tantravahi, Srinivas K.…[et al.]. Survival Outcomes and Tumor IMP3 Expression in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma. Journal of Oncology No. 2015 (2015), pp.1-6.
https://search.emarefa.net/detail/BIM-1069560
American Medical Association (AMA)
Tantravahi, Srinivas K.& Albertson, Daniel& Agarwal, Archana M.& Ravulapati, Sowmya& Poole, Austin& Patel, Shiven B.…[et al.]. Survival Outcomes and Tumor IMP3 Expression in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma. Journal of Oncology. 2015. Vol. 2015, no. 2015, pp.1-6.
https://search.emarefa.net/detail/BIM-1069560
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1069560